{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:26Z","timestamp":1791105746280,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":160,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004816.pub4","type":"reference-entry","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T05:45:05Z","timestamp":1294292705000},"source":"Crossref","is-referenced-by-count":110,"title":["Statins for the primary prevention of cardiovascular disease"],"prefix":"10.1002","author":[{"given":"Fiona","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa HM","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"10.1002\/14651858.CD004816.pub4-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.90.4.1679","article-title":"Effect of lovastatin on early carotid atherosclerosis and cardiovascular events","volume":"90","author":"Furberg","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB2|cit2","unstructured":"Brookes L Nakamura H MEGA: Management of elevated cholesterol in the primary prevention group of adult Japanese American Heart Association 2005 Scientific Sessions 2008"},{"key":"10.1002\/14651858.CD004816.pub4-BIB3|cit3","doi-asserted-by":"crossref","unstructured":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels Circulation Journal 2004 860 7","DOI":"10.1253\/circj.68.860"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB4|cit4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0021-9150(00)80615-2","article-title":"The design and background characteristics of the study on the primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels (Japanese Mega Study)","volume":"151","author":"Nakamura","year":"2000","journal-title":"Atherosclerosis"},{"issue":"20","key":"10.1002\/14651858.CD004816.pub4-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"Journal of the American Medical Association"},{"issue":"26","key":"10.1002\/14651858.CD004816.pub4-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"New England Journal of Medicine."},{"issue":"7","key":"10.1002\/14651858.CD004816.pub4-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004816.pub4-BIB8|cit8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0021-9150(99)00434-7","article-title":"Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study","volume":"151","author":"Baldassarre","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub4-BIB9|cit9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9343(96)00333-6","article-title":"Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study","volume":"101","author":"Mercuri","year":"1996","journal-title":"American Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004816.pub4-BIB10|cit10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01419825","article-title":"Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS Study","volume":"11","author":"Sirtori","year":"1995","journal-title":"International Journal of Cardiac Imaging"},{"key":"10.1002\/14651858.CD004816.pub4-BIB11|cit11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB12|cit12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 Diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.310.6987.1105","article-title":"The impact of health care advice given in primary care on cardiovascular risk","volume":"310","author":"Lindholm","year":"1995","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB14|cit14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2796.1996.492831000.x","article-title":"Changes in cardiovascular risk factors by combined pharmacological strategies: the main results of the CELL Study","volume":"240","author":"Lindholm","year":"1996","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.310.6987.1105","article-title":"The impact of health care advice given in primary care on cardiovascular risk","volume":"310","author":"Lindholm","year":"1995","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB16|cit16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2796.1996.492831000.x","article-title":"Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study","volume":"240","author":"Lindholm","year":"1996","journal-title":"Journal of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub4-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD004816.pub4-BIB18|cit18","first-page":"387","article-title":"Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives","volume":"178","author":"Sigmund","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub4-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/01.CIR.92.7.1758","article-title":"Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries","volume":"92","author":"Salonen","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB20|cit20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of Choleterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of anti-hypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS- a randomised double blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD004816.pub4-BIB22|cit22","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of anti-hypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS- a randomised double blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD004816.pub4-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbinuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/bmj.315.7122.1577","article-title":"The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin","volume":"315","author":"Caro","year":"1997","journal-title":"British Medical Journal"},{"issue":"20","key":"10.1002\/14651858.CD004816.pub4-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"33","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub4-BIB26|cit26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0895-4356(92)90068-X","article-title":"A coronary primary prevention study of Scottish men aged 45-64 years: trial design","volume":"45","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB27|cit27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9149(96)00863-6","article-title":"Baseline risk factors and their associations with outcome in the West of Scotland Coronary Prevention Study","volume":"79","year":"1997","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/oxfordjournals.eurheartj.a015165","article-title":"Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study","volume":"18","year":"1997","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(96)04292-4","article-title":"West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials","volume":"348","year":"1996","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin versus usual care","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub4-BIB32|cit32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199502233320802","article-title":"The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion","volume":"332","author":"Anderson","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004816.pub4-BIB33|cit33","first-page":"S1","article-title":"Anglo-Scandinavian Cardiac Outcomes Trial ASCOT. Main protocol summary & sub-study protocols","volume":"15","author":"O'Brien","year":"2001","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD004816.pub4-BIB36|cit34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB34|cit35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00392-003-0967-7","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cariac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"92","author":"Sever","year":"2003","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"key":"10.1002\/14651858.CD004816.pub4-BIB35|cit36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"19","author":"Sever","year":"2001","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD004816.pub4-BIB37|cit37","first-page":"165","article-title":"Statin therapy for hypertensive patients","volume":"124","author":"Svilaas","year":"2004","journal-title":"Tidsskrift for Den Norske Laegeforening"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB38|cit38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1365-2796.1998.00350.x","article-title":"Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease","volume":"244","author":"Bak","year":"1998","journal-title":"Journal of Internal Medicine."},{"key":"10.1002\/14651858.CD004816.pub4-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low dose metaprolol CR\/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study","volume":"103","author":"Hedblad","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0002-9149(91)90182-K","article-title":"Long-Term Safety and Efficacy Profile of Simvastatin","volume":"68","author":"Boccuzzi","year":"1991","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub4-BIB41|cit41","first-page":"345","article-title":"Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients","volume":"33","author":"Branchi","year":"1995","journal-title":"International Journal of Clinical Pharmacology & Therapeutics."},{"key":"10.1002\/14651858.CD004816.pub4-BIB42|cit42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0021-9150(93)90049-Z","article-title":"Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels","volume":"99","author":"Cassader","year":"1993","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub4-BIB43|cit43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.28.4.647","article-title":"Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects","volume":"28","author":"Chan","year":"1996","journal-title":"Hypertension."},{"issue":"2","key":"10.1002\/14651858.CD004816.pub4-BIB44|cit44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.9.99","article-title":"Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) study","volume":"9","author":"Saito","year":"2002","journal-title":"Journal of Athersclerosis and Thrombosis"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB45|cit45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly. results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Archives of Internal Medicine."},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB46|cit46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1997.tb00971.x","article-title":"Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study","volume":"45","author":"Santanello","year":"1997","journal-title":"Journal of the American Geriatric Society"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB47|cit47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin with that of lovastatin, pravastatin, simvastatin and fluvastatin in patients With hypercholesterolemia (the CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0735-1097(99)00018-2","article-title":"Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile","volume":"33","author":"Dangas","year":"1999","journal-title":"Journal of the American College of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub4-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia","volume":"79","author":"Davidson","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"5-6","key":"10.1002\/14651858.CD004816.pub4-BIB50|cit50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1440-1681.2001.03458.x","article-title":"Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study","volume":"28","author":"Duffy","year":"2001","journal-title":"Clinical & Experimental Pharmacology & Physiology."},{"key":"10.1002\/14651858.CD004816.pub4-BIB51|cit51","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.89.6.2519","article-title":"Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia","volume":"89","author":"Egashira","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB52|cit52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","article-title":"Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care","volume":"243","author":"Eriksson","year":"1998","journal-title":"Journal of Internal Medicine."},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB53|cit53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub4-BIB54|cit54","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/0002-9149(90)90440-C","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia","volume":"66","author":"Bradford","year":"1990","journal-title":"American Journal of Cardiology."},{"issue":"7","key":"10.1002\/14651858.CD004816.pub4-BIB55|cit55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up","volume":"74","author":"Bradford","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"1B","key":"10.1002\/14651858.CD004816.pub4-BIB56|cit56","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/0002-9343(91)90052-Y","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia","volume":"91","author":"Bradford","year":"1991","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub4-BIB57|cit57","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","article-title":"Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST)","volume":"39","author":"Sawayama","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"37","key":"10.1002\/14651858.CD004816.pub4-BIB58|cit58","first-page":"1736","article-title":"Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study","volume":"123","author":"Ferrari","year":"1993","journal-title":"Schweizerische Medizinische Wochenschrift [Journal Suisse de Medecine]"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub4-BIB59|cit59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1463-1326.2000.00106.x","article-title":"Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia","volume":"2","author":"Gentile","year":"2000","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD004816.pub4-BIB60|cit60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0002-9149(97)89140-0","article-title":"The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg\/dl","volume":"77","author":"Glasser","year":"1996","journal-title":"The American Journal Of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB61|cit61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0021-9150(01)00765-1","article-title":"Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reducatase inhibitor, of patients with heterozygous familial hypercholesterolemia","volume":"163","author":"Noji","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub4-BIB62|cit62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ndt\/15.5.684","article-title":"Effects of atorvastatin on dyslipidemia in uraemic patients on peritoneal dialysis","volume":"15","author":"Hufnagel","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub4-BIB63|cit63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0011-393X(96)80050-6","article-title":"Efficacy and safety of simvastatin in current clinical practice: The Italian Family Physician Simvastatin Study","volume":"57","author":"Cattin","year":"1996","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub4-BIB64|cit64","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post hoc analysis of the ALERT study","volume":"4","author":"Jardine A. Holdaas","year":"2006","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB65|cit65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/clc.4960140211","article-title":"Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study","volume":"14","author":"Jones","year":"1991","journal-title":"Clinical Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub4-BIB66|cit66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5551\/jat1994.3.95","article-title":"A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group","volume":"3","year":"1996","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB67|cit67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0021-9150(00)80166-5","article-title":"Abstract at XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29 2000. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS)","volume":"151","author":"Sasaki","year":"2000","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub4-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.162.12.1395","article-title":"Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study","volume":"162","author":"Lemaitre","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB69|cit69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.CIR.0000050380.64025.07","article-title":"Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease","volume":"107","author":"McDermott","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub4-BIB71|cit71","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"American Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004816.pub4-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(97)00695-4","article-title":"Effects of lovastatin on the immune system","volume":"80","author":"Muldoon","year":"1997","journal-title":"American Journal of Cardiology."},{"issue":"Suppl. 71","key":"10.1002\/14651858.CD004816.pub4-BIB73|cit73","first-page":"S","article-title":"Simvastatin in nephrotic syndrome","volume":"56","author":"Olbricht","year":"1999","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub4-BIB74|cit74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000023559","article-title":"Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause","volume":"53","author":"Ohta","year":"2000","journal-title":"Hormone Research."},{"issue":"1-2","key":"10.1002\/14651858.CD004816.pub4-BIB75|cit75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-9150(97)88689-3","article-title":"Abstract of the 11th Internationial Symposium on Atherosclerosis Paris, 5-9 October 1997. 2.P.51 Escape phenomenon during the long-term administration of pravastatin for hyperlipidemia associated with diabetes","volume":"134","author":"Oi","year":"1997","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB76|cit76","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/appi.psy.44.5.412","article-title":"Behavioral implications of lowering cholesterol levels: a double-blind pilot study","volume":"44","author":"Ormiston","year":"2003","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub4-BIB77|cit77","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB78|cit78","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0735-1097(95)80006-3","article-title":"Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)","volume":"26","author":"Buchwald","year":"1995","journal-title":"Journal of American College Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub4-BIB79|cit79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00000658-199210000-00001","article-title":"Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease","volume":"216","author":"Buchwald","year":"1992","journal-title":"Annals of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD004816.pub4-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1992.03490110067031","article-title":"Changes in sequential coronary arteriograms and subsequent coronary events","volume":"268","author":"Buchwald","year":"1992","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004816.pub4-BIB81|cit81","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia","volume":"323","author":"Buchwald","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub4-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol\/liter (200 to 300 mg\/dl) plus two additional atherosclerotic risk factors","volume":"72","year":"1993","journal-title":"American Journal of Cardiology."},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB91|cit83","first-page":"48","article-title":"Pravastatin benefits elderly patients: results of PROSPER study","volume":"14","year":"2003","journal-title":"Cardiovascular Journal of Southern Africa"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub4-BIB83|cit84","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0197-2456(02)00228-3","article-title":"Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial","volume":"23","author":"Avorn","year":"2002","journal-title":"Controlled Clinical Trials"},{"issue":"9363","key":"10.1002\/14651858.CD004816.pub4-BIB84|cit85","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(03)12878-4","article-title":"More on PROSPER","volume":"361","author":"Baztan","year":"2003","journal-title":"Lancet"},{"issue":"9259","key":"10.1002\/14651858.CD004816.pub4-BIB85|cit86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(05)71808-0","article-title":"Dementia and statins. PROSPER study group","volume":"357","author":"Blauw","year":"2001","journal-title":"Lancet"},{"issue":"9346","key":"10.1002\/14651858.CD004816.pub4-BIB86|cit87","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(02)11650-3","article-title":"High-risk elderly patients PROSPER from cholesterol-lowering therapy","volume":"360","author":"Collins","year":"2002","journal-title":"Lancet"},{"issue":"9355","key":"10.1002\/14651858.CD004816.pub4-BIB87|cit88","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)12398-7","article-title":"The PROSPER trial","volume":"361","author":"Fiorenza","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB88|cit89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1468-6708-3-8","article-title":"A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): screening experience and baseline characteristics","volume":"3","author":"Ford","year":"2002","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub4-BIB89|cit90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.73.4.385","article-title":"Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk","volume":"73","author":"Houx","year":"2002","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry."},{"issue":"12","key":"10.1002\/14651858.CD004816.pub4-BIB90|cit91","first-page":"809","article-title":"The PROSPER Study (PROspective study of pravastatin in the elderly at risk)","volume":"57","author":"Kulbertus","year":"2002","journal-title":"Revue Medicale de Liege"},{"key":"10.1002\/14651858.CD004816.pub4-BIB94|cit92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1567-5688(03)90003-1","article-title":"Preventing the next event in the elderly: the PROSPER perspective","volume":"4","author":"Shepherd","year":"2003","journal-title":"Atherosclerosis Supplements"},{"issue":"9346","key":"10.1002\/14651858.CD004816.pub4-BIB92|cit93","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet."},{"issue":"10","key":"10.1002\/14651858.CD004816.pub4-BIB93|cit94","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","article-title":"The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk","volume":"84","author":"Shepherd","year":"1999","journal-title":"American Journal of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub4-BIB95|cit95","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-120-7-199404010-00002","article-title":"Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients","volume":"120","author":"Sprecher","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB96|cit96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/107424849700200102","article-title":"Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2mg daily in subjects with primary hypercholesterolemia","volume":"2","author":"Stein","year":"1997","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB97|cit97","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0002-9149(00)01004-3","article-title":"Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension","volume":"86","author":"Su","year":"2000","journal-title":"American Journal of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub4-BIB98|cit98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-8981(01)00589-7","article-title":"A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia","volume":"312","author":"Akira","year":"2001","journal-title":"Clinica Chimica Acta"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB99|cit99","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney International."},{"key":"10.1002\/14651858.CD004816.pub4-BIB100|cit100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB101|cit101","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/bmj.327.7418.788","article-title":"Taking Simvastatin in the morning compared with in the evening: randomised controlled trial","volume":"327","author":"Wallace","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB102|cit102","first-page":"S42","article-title":"Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia","volume":"136","author":"Yu-An","year":"1998","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1002\/14651858.CD004816.pub4-BIB103|cit103","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB104|cit104","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(07)60084-1","article-title":"Are lipid-lowering guidelines evidence-based?","volume":"369","author":"Abramson","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub4-BIB105|cit105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"9493","key":"10.1002\/14651858.CD004816.pub4-BIB106|cit106","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB107|cit107","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/heart.89.3.327","article-title":"Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised controlled trials of statins 1990 to 2001","volume":"89","author":"Bartlett","year":"2003","journal-title":"Heart"},{"issue":"38","key":"10.1002\/14651858.CD004816.pub4-BIB108|cit108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9380","article-title":"The causes and effects of socio-demographic exclusions from clinical trials","volume":"9","author":"Bartlett","year":"2005","journal-title":"Health Technology Assessment"},{"issue":"9","key":"10.1002\/14651858.CD004816.pub4-BIB109|cit109","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jclinepi.2006.12.006","article-title":"Systematic reviewers neglect bias that results from trials stopped early for benefit","volume":"60","author":"Bassler","year":"2007","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB110|cit110","unstructured":"Beers MH Berkow R (Eds) The Merck Manual of Diagnosis and Therapy. http:\/\/www.merck.com (accessed 20 November 2003)"},{"key":"10.1002\/14651858.CD004816.pub4-BIB111|cit111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/CIRCULATIONAHA.108.800235","article-title":"Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease","volume":"119","author":"Berry","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub4-BIB112|cit112","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.STR.28.5.946","article-title":"Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors","volume":"28","author":"Blauw","year":"1997","journal-title":"Stroke"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub4-BIB113|cit113","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2004.04.022","article-title":"Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials","volume":"117","author":"Briel","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB114|cit114","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub4-BIB115|cit115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","article-title":"Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations","volume":"303","author":"Chen","year":"1991","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB116|cit116","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB117|cit117","first-page":"1670","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials","volume":"376","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB118|cit118","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004816.pub4-BIB119|cit119","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.1992.03480010078028","article-title":"Plasma cholesterol concentrations and mortality in the Whitehall study","volume":"267","author":"Davey Smith","year":"1992","journal-title":"Journal of American Medical Association"},{"key":"10.1002\/14651858.CD004816.pub4-BIB120|cit120","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB121|cit121","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/qshc.7.4.232","article-title":"Cholesterol and heart disease: screening and treatment","volume":"7","author":"Ebrahim","year":"1998","journal-title":"Quality in Health Care"},{"issue":"19","key":"10.1002\/14651858.CD004816.pub4-BIB122|cit122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3190","article-title":"What role for statins? A review and economic model","volume":"3","author":"Ebrahim","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD004816.pub4-BIB123|cit123","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","article-title":"Selected major risk factors and global and regional burden of disease","volume":"360","author":"Ezzati","year":"2002","journal-title":"The Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB124|cit124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1377\/hlthaff.26.1.13","article-title":"Reducing the growing burden of cardiovascular disease in the developing world","volume":"26","author":"Gaziano","year":"2007","journal-title":"Health Affairs"},{"key":"10.1002\/14651858.CD004816.pub4-BIB125|cit125","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD004816.pub4-BIB126|cit126","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1056\/NEJMe0808320","article-title":"Expanding the Orbit of Primary Prevention -Moving beyond JUPITER","volume":"359","author":"Hlatky","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB127|cit127","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","year":"2003","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB128|cit128","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ije\/26.6.1191","article-title":"Serum total cholesterol and risk of hospitalisation, and death from respiratory disease","volume":"26","author":"Iribarren","year":"1997","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB129|cit129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.0306-5251.2001.01478.x","article-title":"Statins for primary prevention: at what coronary risk is safety assured?","volume":"52","author":"Jackson","year":"2001","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub4-BIB130|cit130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/oxfordjournals.aje.a009314","article-title":"Reduced cholesterol is associated with recent minor illness. The CARDIA study","volume":"146","author":"Jacobs","year":"1997","journal-title":"American Journal of Epidemiology"},{"issue":"25","key":"10.1002\/14651858.CD004816.pub4-BIB131|cit131","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: A systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB132|cit132","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/oxfordjournals.aje.a009830","article-title":"Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: A meta-meta-analysis","volume":"149","author":"Katerndahl","year":"1999","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub4-BIB133|cit133","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB134|cit134","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004816.pub4-BIB135|cit135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB136|cit136","series-title":"Paper presented at the Fourth International Cochrane Colloquium 20-24 Oct 1996","article-title":"Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE","author":"Lefebvre","year":"1996"},{"key":"10.1002\/14651858.CD004816.pub4-BIB137|cit137","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/S0140-6736(07)61699-7","article-title":"Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs","volume":"370","author":"Lim","year":"2007","journal-title":"Lancet"},{"issue":"1419","key":"10.1002\/14651858.CD004816.pub4-BIB138|cit138","first-page":"1","article-title":"Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modeling study","volume":"332","author":"Manuel","year":"2006","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB139|cit139","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, 000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD004816.pub4-BIB140|cit140","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub4-BIB141|cit141","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well\u00adbeing","volume":"108","author":"Muldoon","year":"2000","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB142|cit142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bmj.322.7277.11","article-title":"Cholesterol reduction and non\u00adillness mortality: meta\u00adanalysis of randomised clinical trials","volume":"322","author":"Muldoon","year":"2001","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB143|cit143","unstructured":"National Institute for Health and Clinical Excellence Technology Appraisal TA94: Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease. 2006 http:\/\/www.nice.org.uk\/TA094 [accessed 10.10.2010]"},{"key":"10.1002\/14651858.CD004816.pub4-BIB144|cit144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.321.7267.983","article-title":"Use of lipid lowering drugs for primary prevention of coronary heart disease: meta\u00adanalysis of randomised trials","volume":"321","author":"Pignone","year":"2000","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB145|cit145","first-page":"1829","article-title":"Collaborative meta-analysis of 61 studies of vascular risk factors (blood cholesterol, blood pressure, body mass index, diabetes) and cause-specific mortality","volume":"370","year":"2007","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB146|cit146","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(96)05516-X","article-title":"Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table","volume":"348","author":"Ramsay","year":"1996","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004816.pub4-BIB147|cit147","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub4-BIB148|cit148","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD004816.pub4-BIB149|cit149","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic reviews in health care. Meta-analysis in context","author":"Sterne","year":"2001"},{"issue":"21","key":"10.1002\/14651858.CD004816.pub4-BIB150|cit150","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB151|cit151","unstructured":"Jauca C Wright JM Do statins have a role in primary prevention? Therapeutics Letter 2003"},{"key":"10.1002\/14651858.CD004816.pub4-BIB152|cit152","unstructured":"Wright JM Do statins have a role in primary prevention? An update Therapeutics Letter 2010"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub4-BIB153|cit153","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5414\/CPP41567","article-title":"Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials","volume":"41","author":"Vrecer","year":"2003","journal-title":"International Journal of Clinical Pharmacology Therapeutics"},{"key":"10.1002\/14651858.CD004816.pub4-BIB154|cit154","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.328.7436.385","article-title":"Variations and increase in use of statins across Europe","volume":"328","author":"Walley","year":"2004","journal-title":"British Medical Journal"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub4-BIB155|cit155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD004816.pub4-BIB156|cit156","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmj.313.7049.75","article-title":"Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration","volume":"313","author":"Wardle","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004816.pub4-BIB157|cit157","article-title":"Cardiovascular disease","volume-title":"The World Health report. Accessed online at www.who.int\/cardiovascular_diseases\/en\/2008 September 30th","author":"WHO","year":"2008"},{"key":"10.1002\/14651858.CD004816.pub4-BIB158|cit158","volume-title":"2008-2013 Action Plan for the global strategy for the prevention and control of noncommunicable diseases","year":"2008"},{"issue":"13","key":"10.1002\/14651858.CD004816.pub4-BIB159|cit159","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub4-BIB160|cit160","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1161\/hc4601.099487","article-title":"Global burden of cardiovascular diseases. Part 1: General considerations, the epidemic transition, risk factors, and impact of urbanisation","volume":"104","author":"Yusuf","year":"2001","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004816.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004816.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:40:26Z","timestamp":1628545226000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004816.pub4"}},"subtitle":[],"editor":[{"given":"Fiona","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":160,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004816.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004816.pub5","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2011,1,19]]}}}